Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1861 to 1875 of 9090 results

  1. Baxdrostat for treating uncontrolled or resistant hypertension [ID6623]

    In development Reference number: GID-TA11818 Expected publication date:  14 April 2027

    Technology appraisal guidance
    In development

  2. Norucholic acid for treating primary sclerosing cholangitis [ID6583]

    Awaiting development Reference number: GID-TA11782 Expected publication date:  29 April 2027

    Technology appraisal guidance
    Awaiting development

  3. Ex-situ machine perfusion devices to preserve deceased donor livers for transplantation

    In development Reference number: GID-HTG10874 Expected publication date:  20 August 2026

    HealthTech guidance
    In development

  4. Teplizumab for delaying progression of stage 3 type 1 diabetes in people 8 years and over [TSID12403]

    Awaiting development Reference number: GID-TA12037 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Deucravacitinib for treating systemic lupus erythematosus [TSID12405]

    Awaiting development Reference number: GID-TA12035 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Mezigdomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatment lines [TSID12402]

    Awaiting development Reference number: GID-TA12030 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440]

    In development Reference number: GID-TA11554 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Alcohol Use Disorders (update)

    In development Reference number: GID-NG10445 Expected publication date: TBC

    NICE guideline
    In development

  9. Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment [ID6474]

    In development Reference number: GID-TA11613 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Extravascular implantable cardioverter defibrillator insertion for preventing sudden cardiac death caused by ventricular arrhythmia

    In development Reference number: GID-HTG10882 Expected publication date:  08 April 2027

    HealthTech guidance
    In development

  11. Monofocal intraocular lenses for cataract surgery

    In development Reference number: GID-HTG10875 Expected publication date:  10 March 2027

    HealthTech guidance
    In development

  12. 12 SQ-HDM SLIT for treating allergic rhinitis caused by house dust mites in children 5 to 11 years [ID6510]

    In development Reference number: GID-TA11635 Expected publication date:  26 August 2026

    Technology appraisal guidance
    In development

  13. Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years [ID6537]

    In development Reference number: GID-TA11636 Expected publication date:  26 August 2026

    Technology appraisal guidance
    In development

  14. Orforglipron for treating obstructive sleep apnoea associated with obesity or overweight [ID6706]

    Awaiting development Reference number: GID-TA11916 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma after surgery and radiotherapy [ID6659]

    In development Reference number: GID-TA11869 Expected publication date:  24 March 2027

    Technology appraisal guidance
    In development